Fundraising Fox

Avego BioScience Capital β€” Full Portfolio

38 tracked investments Β· listed companies and verified rows first

Caribou Biosciencescariboubio.comin𝕏NASDAQ: CRBU

Caribou Biosciences is a clinical-stage biopharmaceutical company developing CRISPR genome-editing therapies, including off-the-shelf CAR-T cell therapies for hematologic malignancies and armored cell therapies using its Cas12a chRDNA platform.

BiotechMedical DevicesBerkeley, US

Jennifer Doudna(Co-founder)Rachel Haurwitz(President and Chief Executive Officer, Co-founder)Martin Jinek(Co-founder)Andrew May(Executive Officer)

BoardJenny Rooke(Director)Robert Weisskoff(Director)in

Co-investorsAliment CapitalF-Prime CapitalIA Seed VenturesMission Bay CapitalMission BiocapitalPontifax AgTech+2 more

Immunocoreimmunocore.cominNASDAQ: IMCRJul 2022

Immunocore is a biotechnology company developing T cell receptor (TCR) based immunomodulating therapies for patients with cancer, infectious diseases, and autoimmune diseases.

BiotechHealthtechAbingdon, Oxfordshire

Brian Di Donato(Chief Financial Officer)David Berman(Head of Research and Development)Tina St. Leger(Chief Human Resources Officer)Bahija Jallal(Chief Executive Officer)Robert Perez(Director)Peter Ratcliffe(Director)

Co-investorsJDRF T1D Fund

Jasper Therapeuticsjaspertherapeutics.cominNASDAQ: JSPRJul 2026

Jasper Therapeutics develops briquilimab, a targeted anti-KIT monoclonal antibody designed to deplete mast cells for treating chronic immunological and inflammatory diseases.

BiotechHealthtechRedwood City, US

Judith Shizuru(Director)Herb Cross(Executive Officer)Jeet Mahal(Executive Officer, Director)Patrick Crutcher(Director)Svetlana Lucas(Director)Wenru Song(Executive Officer)

Co-investorsTSVCAbingworthIkarian Capital

MapLight TherapeuticsNASDAQ: MPLT

Biotech company developing therapies (Series D-stage).

Alentisalentis.chinβœ“ verified

Alentis is a biotech company developing therapies for chronic liver disease, fibrosis, and cancer based on the molecular biology of liver disease.

AI & Machine LearningBiotechHealthtechMedical DevicesBasel, CH

Thomas Baumert(Founder)Mark Pruzanski(Chief Executive Officer)Luigi Manenti(Chief Medical Officer)Jon Freve(Chief Financial Officer)Bryan Yoon(General Counsel and Chief Administrative Officer)Aditya Venugopal(Chief Business Officer)

Co-investorsBioMedPartnersFrazier Life SciencesJeito CapitalLongitude CapitalNovo HoldingsOrbiMed+5 more

Alimera Sciences

Global pharmaceutical company focused on retinal health.

Alto Pharmacyalto.comin𝕏

Alto Pharmacy is a full-service pharmacy that offers patients medication delivery, cost transparency, and pharmacist access.

ConsumerDigital HealthHealthtechSan Francisco, US

James Karraker(Executive Officer, Director)Mattieu Gamache-Asselin(Founder & CEO)inNichola Eliovits(Director)Nathaniel Kan(Director)Robert Spinner(Director)

BoardNeil Shah(Director)in

Co-investorsBantam GroupCalm VenturesCSC UpshotEvolution VC PartnersFlucas VenturesFormus Capital+8 more

Alveus Therapeuticsalveustx.cominDec 2025 Β· $197M

Alveus Therapeutics develops next-generation metabolic and obesity therapies, including its lead asset ALV-100 (in Phase 2) and a preclinical amylin pipeline of peptides, oral small molecules, and novel formats aimed at sustainable weight loss with better tolerability.

BiotechHealthtechLongevityPhiladelphia, US

Raj Kannan(Executive Officer, Director)

BoardClaudio Nessi(Director)inIvan Gergel(Director)inJan Van de Bossche(Director)inGarrett Ingram(Director)Gregory Parekh(Director)

Co-investorsAndera PartnersGlobal BioAccess FundJeito CapitalNew Rhein Healthcare Investors, LLCSeroba Life SciencesAgent Capital+2 more

Antios Therapeuticsantiostherapeutics.comin𝕏

Antios Therapeutics develops antiviral therapies for hepatitis B virus (HBV) and other viral diseases, including its Active Site Polymerase Inhibitor Nucleotide (ASPIN) ATI-2173 and a capsid assembly modulator program.

BiotechHealthtechMendham, US

Gregory Mayes(Executive Officer, Director)Douglas Mayers(Executive Officer)Tamra Adams(Executive Officer)Abel De La Rosa(Director)

BoardIyona Rajkomar(Director)inBenjamin Rovinski(Director)

Co-investorsAisling CapitalAltium CapitalPontifax Venture Capital

Arch Oncology Incarchoncology.com

Co-investorsBioGenerator VenturesPerot JainRiverVest Venture Partners

Aro Biotherapeuticsarobiotx.comin𝕏

Aro Biotherapeutics develops tissue-targeted genetic medicines using a proprietary protein technology called Centyrins.

BiotechHealthtechPhiladelphia, US

Susan B Dillon(Executive Officer, Director)Karyn O'Neil(Executive Officer, Director)Susan Dillon(Founder)Mark V. Laurenzi(Executive Officer)

BoardElizabeth Anderson(Director)Bruce Peacock(Director)

Co-investorsHealthCapAgent Capital

Atomvieatomvie.comin

AtomVie is a contract development and manufacturing organization (CDMO) in the radiopharmaceutical industry, providing cGMP manufacturing and global distribution of radiopharmaceuticals used to treat and diagnose diseases such as cancer.

Advanced ManufacturingBiotechHealthtech

AtomVie Global Radiopharma

Global CDMO for GMP manufacturing and distribution of radiopharmaceuticals.

CellBxcellbio.comin

Xcell Biosciences develops the AVATAR platform, which integrates physiologic oxygen and pressure control into cell therapy R&D and GMP manufacturing workflows to condition cells for the tumor microenvironment.

BiotechHardwareHealthtech

Co-investorsDynamk Capital

CellCentriccellcentric.comin𝕏

CellCentric is a clinical-stage biopharmaceutical company developing inobrodib, an oral small molecule inhibitor of the p300/CBP proteins, for the treatment of multiple myeloma and other cancers.

BiotechMedical Devices

Co-investorsFuture Planet CapitalVenrock

Digitally-powered pharmacy company
Ellie Diagnostics

Leading independent diagnostic provider for veterinarians in the United States.

Enshorxenshorx.comin

Ensho is a biopharmaceutical company developing NSHO-101, an oral, selective small molecule Ξ±4Ξ²7 inhibitor intended as a once-daily treatment for patients with inflammatory bowel disease (IBD).

BiotechHealthtechMorris Plains, US

Neena Bitritto-Garg(Founder)Gerhard Hagn(Chief Executive Officer)Danielle Fry(Chief Operating Officer and Chief Legal Officer)Tory Trippe(Vice President, Head of Finance and Corporate Development)Matthew R. Warr(Senior Vice President, Research & Head of Biology)Andy Whitney(Chief Scientific Officer)

Co-investorsGlobal BioAccess Fund

Epi Biologicsepibiologics.comin

Epibiologics develops protein degradation medicines using protein sciences and antibody engineering capabilities.

BiotechMedical DevicesSan Mateo, US

Ann Lee-Karlon(Executive Officer, Director)Mitchell Mutz(Executive Officer, Director)James Wells(Director)

BoardSamuel Bjork(Director)Alexandra Cantley(Director)Seiji Miyahara(Director)

Co-investorsGV (Google Ventures)Mission BiocapitalNovartis Venture FundRoche Venture FundSamsara BioCapitalTaiho Ventures, LLC+3 more

Evommuneevommune.comin

Evommune develops therapies targeting the underlying sources of chronic inflammatory diseases, aiming to provide underserved patient populations with more than symptomatic relief.

BiotechHealthtechPalo Alto, US

Luis Pena(Executive Officer, Director)Janice Drew(Executive Officer)David Cohen(Director)Gregory Moss(Executive Officer)Eugene Bauer(Executive Officer, Director)Francois Beaubien(Director)

Co-investorsAndera PartnersB Capital GroupB4 CapitalBeiersdorf Innovation FundFemHealth VenturesLongwood Fund+2 more

Eyevance Pharmaceuticals

US ophthalmic pharmaceutical company.

Health prediction company using proteomics
Healthoutlookhealthoutlook.comin

HealthOutlook applies life sciences and machine learning methods to predict health outcomes.

AI & Machine LearningBiotechDigital Health

Maplightrxmaplightrx.comin

MapLight is a biotech company developing therapeutics for central nervous system disorders, using a discovery platform that combines optogenetics, STARmap, and transcriptomics to identify and target specific brain circuits.

BiotechHealthtech

Memento MedicinesJun 2026

Privately-held biotech company developing biologic therapies for retinal diseases

BiotechBoston, US

William Daley Bonificio(Executive Officer, Promoter)Stephen Basil Thomas(Executive Officer, Promoter)Naveen Manu Daryani(Executive Officer, Director, Promoter)

BoardZach Scheiner(Director)inMegan Krench(Director)Dmitrij Hristodorov(Director)in

Co-investorsSanofi VenturesForbionRA CapitalSamsara BioCapital

Mytomorrowsmytomorrows.comin𝕏

myTomorrows operates an online platform and patient navigation service that helps patients and their physicians discover and access clinical trials, expanded access programs, and treatments in development.

BiotechDigital HealthHealthtech

Ronald Brus(Founder, MD)

Co-investorsBalderton Capital

NAV Fund Servicesnavfundservices.comin

NAV Fund Services is a fund administration provider serving hedge funds, private equity, venture capital, private credit, real estate, digital asset funds, family offices, and multi-manager platforms, offering trade reconciliation, portfolio valuation, fee calculation, NAV statements, tax/K-1, and investor reporting.

Enterprise SoftwareFintechSaaS

Co-investorsHivemind Capital LLCHivemind Capital Partners

PBS Biotechpbsbiotech.comin𝕏

PBS Biotech develops Vertical-Wheel bioreactors and related accessories for scalable manufacturing of cell therapies, including allogeneic therapies derived from induced pluripotent stem cells, mesenchymal stem cells, and CAR-T or NK cells.

BiotechHardwareMedical DevicesCamarillo, US

Brian Lee(Executive Officer, Director)Matt Croughan(Executive Officer)Nelson Bermudez(Executive Officer)Terrell Mathews(Executive Officer)Bryan Poltilove(Director)Jung Lim(Director)

Ribon Therapeuticsin

BiotechLexington, US

Victoria M. Richon(Executive Officer, Director)

BoardCameron Wheeler(Director)Jonathan Root(Director)Laurence Lasky(Director)

Co-investorsOUP (Osage University Partners)Peregrine VenturesAbbVieNovartis Venture FundThe Column Group

Saol Therapeutics

Private specialty pharmaceutical company.

Saolrxsaolrx.comin

Saol Therapeutics is a privately held, clinical-stage pharmaceutical company focused on late-stage clinical development of treatments for CNS disorders such as pain and spasticity, as well as orphan diseases.

BiotechHealthtechRoswell, US

Sebelapharmasebelapharma.comin

Sebela Pharmaceuticals is a U.S. pharmaceutical company developing prescription medicines with a focus on gastroenterology and women's health.

BiotechFemTech

Sentynlsentynl.comin

Sentynl Therapeutics is a pharmaceutical company that develops and commercializes prescription therapies, including ZYCUBO (copper histidinate), which has received FDA approval.

BiotechHealthtech

Specialty pharmaceutical company
T cell receptor biotechnology company
Thumbnail for Escient Pharmaceuticalsescientpharma.com

BiotechSan Diego, US

Alain Baron(Executive Officer, Director)JeenJoo Kang(Director)Robert Tjian(Director)Marcus Boehm(Executive Officer)

BoardAndrew Schwab(Director)in

Co-investors5AM VenturesNew Enterprise Associates (NEA)OUP (Osage University Partners)Sanofi VenturesThe Column GroupAbingworth+3 more

Trextrex.bioin

TRexBio develops Treg-focused biologic therapeutics for autoimmune and inflammatory diseases, using its Deep Biology Platform to analyze regulatory T cell behavior in human tissues and identify therapeutic targets.

AI & Machine LearningBiotechHealthtech

Co-investorsDelos CapitalPfizer Venture InvestmentsAgent Capital

TRexBio

Biotech decoding human tissue immune biology to create therapeutics.

Co-investorsPfizer Venture InvestmentsSV Health Investors

Rows marked β€œSEC filing” are inferred from directors named on the company's SEC Form D β€” public regulatory data, not a portfolio list published by the firm.